Centauri Therapeutics has bought Alphamer technology from Altermune Technologies for an undisclosed amount, for drug discovery and development.
The company possesses all patent rights, proprietary compounds, know-how and collaboration / licence agreements associated with the immuno-therapeutics platform technology.
Centauri Therapeutics has raised nearly £3m from Animatrix Capital and private investors to fund the development of the first lead Alphamers against anti-microbial resistant (AMR) pathogens.
The AMR pathogens have the ability to withstand attack by antimicrobial drugs, such as antibacterial drugs, antifungals, antivirals, and antimalarials, so that standard treatments become ineffective and infections persist, increasing the risk of spread to others, according to the World Health Organisation.
Centauri Therapeutic chairman Clive Dix said: "The Alphamer platform technology is a unique opportunity to assemble well-characterised building blocks to produce novel and IP-protected medicines. Centauri Therapeutics has assembled a team of industry-experienced R&D scientists guided by a proven leadership."
The company has set up a R&D facility at Discovery Park in Sandwich, Kent, UK.
A team of scientists at the facility will focus on discovering, optimising and developing novel Alphamers to target acute hospital acquired infections.
According to the company, Alphamers are chemically synthesised molecules designed to redirect the body’s own immune system to more effectively combat infection.
Centauri Therapeutics CEO Mike Westby said: "The emergence and rapid global spread of AMR pathogens means that there is a large potential market to treat life-threatening intractable diseases.
"As well as the new financing announced today we are also proud to announce the appointment of Clive Dix as our Chairman. Clive’s experience in successfully developing therapeutic platform technologies will be invaluable."